Tobacco Products Scientific Advisory Committee; Notice of Meeting, 56547-56548 [2010-23057]
Download as PDF
<![CDATA[
56547
Federal Register / Vol. 75, No. 179 / Thursday, September 16, 2010 / Notices
education, and at the option of the State,
where appropriate, mentoring,
counseling, and adult supervision to
promote abstinence from sexual activity,
with a focus on those groups which are
most likely to bear children out-ofwedlock. An expected outcome for all
programs is to promote abstinence from
sexual activity.
OMB approval is requested to solict
comments from the public on
paperwork reduction as it relates to
ACYF’s receipt of the following
documents from applicants and
awardees:
Application for Mandatory Formula
Grant.
State Plan.
Performance Progress Report.
Respondents: 50 States and 9
Territories, to include, District of
Columbia, Puerto Rico, Virgin Islands,
Guam, American Samoa, Northern
Mariana Islands, the Federated States of
Micronesia, the Marshall Islands and
Palau.
ANNUAL BURDEN ESTIMATES
mstockstill on DSKH9S0YB1PROD with NOTICES
Application, to include program narrative ........................................
State Plan ........................................................................................
Performance Progress Reports .......................................................
Estimated Total Annual Burden
Hours: 7,316.
In compliance with the requirements
of Section 506(c)(2)(A) of the Paperwork
Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Administration,
Office of Information Services, 370
L’Enfant Promenade, SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. E-mail address:
infocollection@acf.hhs.gov. All requests
should be identified by the title of the
information collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Dated: September 13, 2010.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2010–23096 Filed 9–15–10; 8:45 am]
BILLING CODE 4184–01–P
VerDate Mar<15>2010
19:19 Sep 15, 2010
Jkt 220001
Number of
responses per
respondent
Number of
respondents
Instrument
59
59
59
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Tobacco Products Scientific Advisory
Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Tobacco
Products Scientific Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on October 7, 2010, from 8 a.m.
until 5 p.m. and on October 8, 2010,
from 8 a.m. to 1 p.m.
Location: FDA White Oak Conference
Center, 10903 New Hampshire Ave.,
Bldg. 31, rm. 1503, Silver Spring, MD
20993–0002. Information regarding
special accommodations due to a
disability, visitor parking, and
transportation may be accessed at:
https://www.fda.gov/Advisory
Committees/default.htm; under the
heading ‘‘Resources for You’’ click on
‘‘White Oak Conference Center Parking
and Transportation Information for FDA
Advisory Committee Meetings.’’
Contact Person: Karen TempletonSomers, Center for Tobacco Products,
Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850,
1–877–287–1373 (choose Option 4),
email: TPSAC@fda.hhs.gov, or FDA
Advisory Committee Information Line,
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Average burden
hours per
response
1
1
2
24
40
30
Total burden
hours
1,416
2,360
3,540
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
8732110002. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On October 7 and 8, 2010,
the committee will hear and discuss
presentations on the publicly available
industry documents as they relate to the
issue of the impact of the use of menthol
in cigarettes on the public health,
including such use among children,
African-Americans, Hispanics, and
other racial and ethnic minorities.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before September 30, 2010.
Oral presentations from the public will
be scheduled between approximately
1:30 p.m. and 2:30 p.m. on October 7,
E:\FR\FM\16SEN1.SGM
16SEN1
56548
Federal Register / Vol. 75, No. 179 / Thursday, September 16, 2010 / Notices
2010. Those desiring to make formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before September 22, 2010. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
September 23, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Karen
Templeton-Somers at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: September 10, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSKH9S0YB1PROD with NOTICES
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
Jkt 220001
Dated: September 10, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group Clinical Trials
Review Committee.
Date: October 25–26, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Keary A Cope, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7190,
Bethesda, MD 20892–7924, 301–435–2222,
copeka@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: September 10, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–23149 Filed 9–15–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
[FR Doc. 2010–23144 Filed 9–15–10; 8:45 am]
Joint Meeting of the Peripheral and
Central Nervous System Drugs
Advisory Committee and the Drug
Safety and Risk Management Advisory
Committee; Notice of Meeting
BILLING CODE 4140–01–P
AGENCY:
Food and Drug Administration,
HHS.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
BILLING CODE 4160–01–S
19:19 Sep 15, 2010
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
F—Manpower & Training.
Date: September 21–22, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: Lynn M. Amende, PhD,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 6116 Executive Blvd., Room
8105, Bethesda, MD 20892, 301–451–4759,
amendel@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to scheduling
conflicts.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
National Institutes of Health
[FR Doc. 2010–23057 Filed 9–15–10; 8:45 am]
VerDate Mar<15>2010
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committees: Peripheral and
Central Nervous System Drugs Advisory
Committee and the Drug Safety and Risk
Management Advisory Committee.
General Function of the Committees:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on November 3, 2010, from 8 a.m.
to 5 p.m.
Location: Hilton Washington DC
North/Gaithersburg, The Ballrooms, 620
Perry Pkwy., Gaithersburg, MD. The
hotel telephone number is 301–977–
8900.
Contact Person: Diem-Kieu Ngo,
Center for Drug Evaluation and
Research, Food and Drug
E:\FR\FM\16SEN1.SGM
16SEN1
]]>Agencies
[Federal Register Volume 75, Number 179 (Thursday, September 16, 2010)]
[Notices]
[Pages 56547-56548]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-23057]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Tobacco Products Scientific Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Tobacco Products Scientific Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on October 7, 2010, from 8
a.m. until 5 p.m. and on October 8, 2010, from 8 a.m. to 1 p.m.
Location: FDA White Oak Conference Center, 10903 New Hampshire
Ave., Bldg. 31, rm. 1503, Silver Spring, MD 20993-0002. Information
regarding special accommodations due to a disability, visitor parking,
and transportation may be accessed at: https://www.fda.gov/AdvisoryCommittees/default.htm; under the heading ``Resources for You''
click on ``White Oak Conference Center Parking and Transportation
Information for FDA Advisory Committee Meetings.''
Contact Person: Karen Templeton-Somers, Center for Tobacco
Products, Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 1-877-287-1373 (choose Option 4), email:
TPSAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-
741-8138 (301-443-0572 in the Washington, DC area), code 8732110002.
Please call the Information Line for up-to-date information on this
meeting. A notice in the Federal Register about last minute
modifications that impact a previously announced advisory committee
meeting cannot always be published quickly enough to provide timely
notice. Therefore, you should always check the agency's Web site and
call the appropriate advisory committee hot line/phone line to learn
about possible modifications before coming to the meeting.
Agenda: On October 7 and 8, 2010, the committee will hear and
discuss presentations on the publicly available industry documents as
they relate to the issue of the impact of the use of menthol in
cigarettes on the public health, including such use among children,
African-Americans, Hispanics, and other racial and ethnic minorities.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
September 30, 2010. Oral presentations from the public will be
scheduled between approximately 1:30 p.m. and 2:30 p.m. on October 7,
[[Page 56548]]
2010. Those desiring to make formal oral presentations should notify
the contact person and submit a brief statement of the general nature
of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
September 22, 2010. Time allotted for each presentation may be limited.
If the number of registrants requesting to speak is greater than can be
reasonably accommodated during the scheduled open public hearing
session, FDA may conduct a lottery to determine the speakers for the
scheduled open public hearing session. The contact person will notify
interested persons regarding their request to speak by September 23,
2010.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Karen Templeton-
Somers at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: September 10, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-23057 Filed 9-15-10; 8:45 am]
BILLING CODE 4160-01-S
